FDA Authorizes Phase 2 Trial for CAR T-Cell Therapy in Brain Metastases

The FDA has granted clearance for a Phase 2 clinical study of MT027, an allogeneic CAR T-cell therapy targeting B7-H3. This trial will investigate the treatment in patients with brain metastases originating from lung or breast cancer. This development represents a significant step in exploring new therapeutic avenues for these challenging and often difficult-to-treat conditions, offering potential hope for patients.